Breakthroughs in cancer treatment are focusing on novel targets and modalities to overcome resistance and improve efficacy. Researchers revealed that targeting TP53-induced glycolysis and apoptosis regulator (TIGAR) can restore antitumor T-cell function in acute myeloid leukemia. Dual blockade of TIGIT and PD-1 immune checkpoints shows promise in difficult hepatocellular carcinoma. CAR T cell therapies are being engineered to penetrate solid tumors more effectively, including innovations such as arming CAR T cells with CRISPR-edited enhancements. Oncolytic viruses expressing IL-12 display encouraging results in solid tumors, reaffirming the role of immunotherapy.